Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 7,566 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasm of Skin Clear all
Completed Phase 1 Interventional Results available

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

NCT01975831
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

NCT01491737
View directory record Official record
Conditions
Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Aromatase Inhibitor, Induction Chemotherapy
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

NCT00631072
View directory record Official record
Conditions
Malignant Melanoma
Interventions
INKT, GM-CSF
Biological · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00735462
View directory record Official record
Conditions
Genital Warts
Interventions
2.5% imiquimod cream, 3.75% imiquimod cream, Placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
43
States / cities
Jonesboro, Arkansas • Carmichael, California • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

NCT02120469
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor-negative, Stage IV Breast Cancer, Triple-negative Breast Carcinoma
Interventions
everolimus, eribulin mesylate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 11, 2026, 7:02 PM EDT
Completed No phase listed Observational Results available

Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.

NCT03024866
View directory record Official record
Conditions
Nonmelanoma Skin Cancer
Interventions
Electronic Brachytherapy
Procedure
Lead sponsor
Xoft, Inc.
Industry
Eligibility
41 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Los Gatos, California • San Diego, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

NCT00546156
View directory record Official record
Conditions
Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
Drug
Lead sponsor
Ian E. Krop, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Hooksett, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Not applicable Interventional Results available

Time Restricted Eating on Cancer Risk

NCT05038137
View directory record Official record
Conditions
Pre-diabetes, Breast Cancer, Time Restricted Feeding
Interventions
Time restricted feeding, Control
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 67 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

NCT05557045
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Solid Tumor, Melanoma, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Anaplastic Thyroid Cancer (ATC)
Interventions
JZP815
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

NCT00558545
View directory record Official record
Conditions
Human Mammary Carcinoma
Interventions
AEG35156
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

NCT00431275
View directory record Official record
Conditions
Melanoma
Interventions
CP-675,206
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Aventura, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer

NCT00096356
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
CoQ10 & Vitamin E, Placebo & Vitamin E
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Santa Rosa, California • Newark, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622
View directory record Official record
Conditions
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
Olaparib, Physician's choice chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
42
States / cities
San Diego, California • Santa Rosa, California • Whittier, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

NCT01693731
View directory record Official record
Conditions
Periodontal Disease, Quality of Life
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

NCT03807765
View directory record Official record
Conditions
Metastatic Breast Cancer, Brain Metastases
Interventions
Nivolumab, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer

NCT00086957
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, docetaxel, gefitinib
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Hemet, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

NCT00246012
View directory record Official record
Conditions
Melanoma
Interventions
Intetumumab, Dacarbazine, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 11, 2026, 7:02 PM EDT
Recruiting Phase 2 Interventional

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

NCT06268665
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Invasive Breast Cancer, Ovarian Cancer, Ovarian Cancer Stage 1, Ovarian Cancer Stage II, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Ovarian Cancer Stage IA, Ovarian Cancer Stage IB, Ovarian Cancer Stage IC, Ovarian Cancer Stage 2, Ovarian Cancer Stage 3, Ovarian Cancer Stage IIIb, Ovarian Cancer Stage IIIC, Breast Cancer Stage IIIA, Breast Cancer Invasive, Breast Cancer, Stage IA, Breast Cancer, Stage IB, Breast Cancer Stage IIA, Breast Cancer Stage IIB, Breast Cancer Stage IIIB, Breast Cancer Stage IIIc, Cancer, Breast, Tumors, Breast, Mammary Cancer, Mammary Carcinoma, Breast Carcinoma, Breast Neoplasm, Malignant Breast Neoplasm, Malignant Tumor of Breast, Cancer of Ovary, Ovary Cancer, Ovary Neoplasm
Interventions
Tart Cherry Juice
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

NCT00050167
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Docetaxel, Capecitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2011 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

NCT05060237
View directory record Official record
Conditions
Actinic Keratosis, Keratosis, Actinic, Keratosis
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 11, 2026, 7:02 PM EDT
Recruiting Not applicable Interventional

Cognitive Rehabilitation Following Breast Cancer Treatment

NCT06545045
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Metacognitive Strategy Training (MCST), Inactive Control Group
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
20 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Active, not recruiting Not applicable Interventional

Robotic vs. Open NSM for Early Stage Breast Cancer

NCT05720039
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Interventions
Robotic NSM, Open NSM
Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 11, 2026, 7:02 PM EDT
Completed Not applicable Interventional

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Nausea and Vomiting, Pain
Interventions
questionnaire administration, hypnotherapy, therapeutic conventional surgery
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 11, 2026, 7:02 PM EDT